Mortalité chez les personnes qui s'injectent des drogues : revue systématique et méta-analyse
La mortalidad entre consumidores de drogas inyectables: una revisión sistemática y meta-análisis
Bradley M MathersI,*; Louisa DegenhardtII; Chiara BucelloII; James LemonII; Lucas WiessingIII; Mathew HickmanIV
IThe Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia
IINational Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
IIIScientific Division, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal
IVSchool of Social and Community Medicine, University of Bristol, Bristol, England
OBJECTIVE: To systematically review cohort studies of mortality among people who inject drugs, examine mortality rates and causes of death in this group, and identify participant- and study-level variables associated with a higher risk of death.
METHODS: Tailored search strings were used to search EMBASE, Medline and PsycINFO. The grey literature was identified through online grey literature databases. Experts were consulted to obtain additional studies and data. Random effects meta-analyses were performed to estimate pooled crude mortality rates (CMRs) and standardized mortality ratios (SMRs).
FINDINGS: Sixty-seven cohorts of people who inject drugs were identified, 14 of them from low- and middle-income countries. The pooled CMR was 2.35 deaths per 100 personyears (95% confidence interval, CI: 2.122.58). SMRs were reported for 32 cohorts; the pooled SMR was 14.68 (95% CI: 13.0116.35). Comparison of CMRs and the calculation of CMR ratios revealed mortality to be higher in low- and middle-income country cohorts, males and people who injected drugs that were positive for human immunodeficiency virus (HIV). It was also higher during off-treatment periods. Drug overdose and acquired immunodeficiency syndrome (AIDS) were the primary causes of death across cohorts.
CONCLUSION: Compared with the general population, people who inject drugs have an elevated risk of death, although mortality rates vary across different settings. Any comprehensive approach to improving health outcomes in this group must include efforts to reduce HIV infection as well as other causes of death, particularly drug overdose.
OBJECTIF: Examiner systématiquement les études de cohortes de la mortalité chez les toxicomanes par injection, étudier les taux de mortalité et les causes de décès dans ce groupe, et identifier les variables, au niveau des participants et des études, associées à un risque accru de décès.
MÉTHODES: Des critères de recherche spécifiquement adaptés ont été utilisés pour les recherches réalisées sur EMBASE, Medline et PsycINFO. La littérature grise a été identifiée par le biais de bases de données de littérature grise disponibles en ligne. Des experts ont été consultés pour obtenir des données et des études supplémentaires. Des méta-analyses des effets aléatoires ont été réalisées afin d'estimer les taux bruts de mortalité (TBM) groupés et les taux de mortalité standardisés (TMS).
RÉSULTATS: Soixante-sept cohortes de personnes qui s'injectent des drogues ont été identifiées, dont 14 appartenant à des pays à revenu faible et intermédiaire. Le TBM groupé était de 2,35 décès pour 100 personnes-années (intervalle de confiance de 95%, IC: 2,12 2,58). Les TMS étaient indiqués pour 32 cohortes, avec un TMS groupé de 14,68 (IC de 95%: 13,01 16,35). La comparaison des TBM et le calcul des taux de TMS ont révélé une mortalité plus élevée parmi les cohortes des pays à revenu faible et intermédiaire, les sujets masculins et les toxicomanes par injection séropositifs. Elle était également plus élevée pendant les périodes d'interruption thérapeutique. L'overdose et le syndrome d'immunodéficience acquise (SIDA) étaient les causes principales des décès parmi ces cohortes.
CONCLUSION: Si l'on compare avec la population globale, les personnes qui s'injectent des drogues ont un risque élevé de décès, bien que les taux de mortalité varient selon les contextes. Toute approche exhaustive visant à améliorer les résultats de ce groupe en matière de santé doit comprendre des efforts en vue de diminuer l'infection par le VIH, ainsi que d'autres causes de décès, notamment l'overdose.
OBJETIVO: Revisar de forma sistemática los estudios de cohortes sobre la mortalidad entre los consumidores de drogas inyectables, examinar las tasas de mortalidad y las causas de muerte en este grupo e identificar las variables relacionadas con el estudio y los participantes asociadas a un mayor riesgo de muerte.
MÉTODOS: Se emplearon cadenas de búsqueda adaptadas para registrar EMBASE, Medline y PsycINFO. La literatura gris se identificó por medio de bases de datos de literatura gris en línea. Se consultaron expertos a fin de obtener datos y estudios adicionales y se llevaron a cabo metaanálisis de efectos aleatorios para calcular las tasas brutas combinadas de mortalidad y las tasas de mortalidad estandarizadas.
RESULTADOS: Se identificaron diecisiete cohortes de consumidores de drogas inyectables, 14 de las cuales en países con ingresos bajos y medios. La tasa bruta combinada de mortalidad fue de 2,35 fallecimientos por cada 100 años-persona (intervalo de confianza del 95%, IC: 2,12-2,58). Se declararon las tasas de mortalidad estandarizadas para 32 cohortes; la tasa bruta combinada de mortalidad fue de 14,68 (IC 95%: 13,01-16,35). La comparación de las tasas brutas combinadas de mortalidad y el cálculo de las proporciones de la mortalidad bruta combinada revelaron que la mortalidad fue superior en las cohortes de países con ingresos bajos y medios, en varones y entre consumidores de drogas inyectables que dieron positivo para el virus de la inmunodeficiencia humana (VIH), así como durante los periodos sin tratamiento. Las sobredosis y el síndrome de la inmunodeficiencia adquirida (SIDA) fueron las causas principales de muerte en las cohortes.
CONCLUSIÓN: En comparación con la población general, los consumidores de drogas inyectables presentan un riesgo elevado de muerte, si bien las tasas de mortalidad varían en los distintos lugares. Cualquier enfoque completo para mejorar los resultados sanitarios en este grupo deberá esforzarse por reducir la infección por VIH, así como las otras causas de muerte, en especial, la sobredosis.
People who use drugs, especially by injection, are at higher risk of dying from both acute and chronic diseases, many of which are related to their drug use, than people who do not use these drugs. Fatal overdose and infection with human immunodeficiency virus (HIV) and other blood-borne viruses transmitted through shared needles and syringes are the most common causes of death in this group.1 Understanding causes of death is important when setting priorities for programmes designed to reduce deaths from the use of drugs. Longitudinal studies of people who inject drugs are critical for assessing the magnitude, nature and correlates of the risk of death in this population.
A systematic review conducted in 2004 identified 30 prospective studies published between 1967 and 2004 that dealt with "problematic drug users" or people who inject drugs.2 These reviews have consistently shown that the practice of injecting drugs is associated with an elevated risk of death, particularly from the complications of HIV infection, drug overdose and suicide. Since these reviews were conducted, the number of studies examining mortality among cohorts of people who inject drugs has risen substantially. This has made it possible to perform fine-grained analyses that were not feasible in earlier reviews. Furthermore, those earlier reviews did not examine the potential impact of study-level variables, variation across countries, or of participant-level variables that could affect both mortality rates and differences in causes of death, yet study-level evidence suggests that males who inject drugs may be at higher risk of dying than females and that different types of drugs are associated with different risks of death.35 Findings from other reviews have also suggested that rates of death among people who are dependent on opioids are different from the rates of death observed in people who are dependent on stimulants such as cocaine and amphetamine type stimulants.35
In recent years the number of studies reporting on mortality among people who inject drugs has increased. Hence, the objective of this review was to determine the following:
overall crude mortality rates (CMRs) and excess deaths across cohorts of people who inject drugs, by sex;
causes of death across studies, particularly from drug overdose and acquired immunodeficiency syndrome (AIDS); differences in mortality rates and causes of death among HIV-positive (HIV+) and HIV-negative (HIV) people who inject drugs;
differences in mortality rates across cohorts by geographical location and country income level;
mortality rates by type of drug injected (e.g. opioids versus stimulants);
mortality rates during in-treatment and off-treatment periods.
A recent series of reviews identified cohort studies among opioid, amphetamine and cocaine users to examine mortality.35 In these reviews tailored search strings were used to search three electronic databases for studies published between 1980 and 2012: Medline, EMBASE and PsycINFO. The search strings contained keywords and database-specific terms (MeSH headings, EMTREE terms and explode terms; Box 1). All results were limited to human subjects. We identified grey literature sources reporting on mortality by searching online grey literature databases, library databases and the web sites listed in a published technical report.6 To make sure that no relevant papers had been missed, we sent the draft lists of the papers identified through these searches to experts for their review.
For the current study we examined all papers found in the reviews of drug-related mortality but selected only cohorts composed of people who injected opioids and other drugs. We used the strategy outlined in the preceding paragraph to further search for these cohorts. We included in the analysis only studies of drug users that included mortality data disaggregated by participants' injecting drug use; studies were included only if more than 70% of the cohort was composed of people who injected drugs.
The searches yielded a total of 5981 studies of mortality related to the use of opioids, amphetamines and cocaine. We identified another 79 articles by searching the reference lists of reviews on mortality related to drug use. Experts provided additional studies for 16 cohorts. From these 5981 articles we excluded a total of 5762: 4999 did not focus on drug dependence or mortality, 118 did not include raw data, 292 were case series, and 600 had insufficient mortality data on people who inject drugs. In total, we selected 67 cohort studies for inclusion in the analyses (Fig. 1). These studies were further assessed using STROBE reporting guidelines.7
Once we had identified all studies, one of the authors (JL) extracted the data into an Excel database (Microsoft, Redmond, United States of America) and two others rechecked them (BM, CB). This yielded the basic data set for the statistical analyses. We extracted information on the location of each study, the period of recruitment and duration of follow-up, the number of people in the cohort, the percentage of people in the cohort who injected drugs, the number of personyears (PY) of follow-up and the number of deaths.
We extracted CMRs and standardized mortality ratios (SMRs). We expressed CMRs as the number of deaths per 100 PY of follow-up. We reported SMRs as calculated in the source papers. In several cases standard errors, confidence intervals (CIs) and CMRs were not reported, so we estimated them using standard calculations. We also put into the database CMRs and SMRs that were reported according to sex, HIV status, treatment status and type of drug injected, as well as data on deaths from drug overdose or AIDs-related causes.
We included in the analyses studies that specified treatment status if they classified the data by mutually exclusive treatment groups or periods. We only included studies in which the exact dates of entry into and exit from the study had been recorded and used to calculate the number of PYs, the number of deaths and mortality rates.
We performed meta-analyses to estimate pooled all-cause CMRs and all-cause SMRs, and pooled estimates of deaths from specific causes, as in previous reviews.8 To perform the meta-analyses we used the "metan" command in STATA version 10.1 (StataCorp LP, College Station, USA). The "metan" command uses inverse-variance weighting to calculate random effects pooled summary estimates and their confidence limits, true effect differences between studies and study heterogeneity.9,10 Random effects models allow for heterogeneity between and within studies. We expected high levels of heterogeneity between studies because of the marked differences between the samples of people injecting drugs; accordingly, we applied a random effects model to all analyses. The appropriateness of this a priori decision was confirmed by the resultant χ2 and the I-squared statistic. To further investigate this heterogeneity, when the data permitted we divided the cohorts into subgroups and used CMR ratios to compare differences in mortality.11 We made comparisons between subgroups as follows: sex (male versus female); primary drug injected at baseline (opioids versus stimulants); HIV status (HIV+ versus HIV); and treatment for drug dependence (in-treatment period versus off-treatment period).
We examined the following as potential sources of heterogeneity in CMRs or SMRs using random effects univariate meta-regressions in STATA: geographic region, country income group (based on World Bank categories), percentage of sample that injected drugs, were male or were HIV+ at baseline; presence of opioid users in the cohort; and the year in which the follow-up period ended.12,13
We included 67 cohorts in the analysis; 14 were from low- and middle-income countries (Table 1). Studies from Europe, North America and Australasia were the most common; nine studies were from Asia and one was from South America. The pooled CMR across the 65 cohorts for which a CMR was provided was 2.35 deaths per 100 PY (Fig. 2). Cohorts from Asia had the highest pooled CMRs (5.25), followed by the cohorts from North America (2.64) and western Europe (2.31); cohorts from Australasia had the lowest pooled CMR (0.71).
SMRs were reported for 31 cohorts; their pooled SMR was 14.68 (Fig. 3). Since the heterogeneities (I2) of the pooled CMR and SMR were both very high (98.6% and 98.3%, respectively), we stratified estimates by subgroups.
Sex differences in mortality
Thirty-seven studies presented CMRs by sex.14,1719,2124,26,28,3032,34,3638,43,4550,52,54,57,58,62,6672,74 The pooled CMR ratio for males versus females was 1.32 (Fig. 4), which suggests that crude mortality was higher among males. Nineteen studies reported SMRs by sex;14,17,21,24,26,28,30,32,34,38,43,46,52,54,58,66,67,70,74 the pooled CMR ratio suggests that females had significantly greater excess mortality than males in similar age groups in the general population (Fig. 5). Only two of the nineteen studies presented SMRs for males that were greater than those for females.30,74
Causes of death
Several studies reported specific causes of death. The pooled CMR for death from drug overdose was 0.62 per 100 PY across 43 studies (Fig. 6). Eleven studies reported CMRs for death from drug overdose by sex: overall the CMR was 1.38 times higher (Fig. 7) among males than among females.14,17,19,21,24,32,38,49,52,57,58
In 20 studies CMRs were provided separately for people who inject drugs according to their HIV status.15,16,18,28,34,3640,45,48,49,55,57,60,65,70,72,74 All-cause mortality was three times higher among HIV+ than among HIV subjects (CMR ratio: 3.15) (Fig. 8). Much of this elevated mortality appeared to result from AIDS deaths among HIV+ users of injecting drugs. The pooled estimate of AIDS-related mortality for the 16 studies for which data were available was 2.55 per 100 PY (Fig. 9).28,3336,3841,48,49,60,65,70,72,74 When we examined mortality from causes other than AIDS, we found it to be 1.63 times higher among HIV+ than among HIV people who inject drugs (Fig. 10).28,34,36,3840,48,49,60,65,70,72,74
Mortality from drug overdose was presented by HIV status in 9 studies.28,34,36,38,39,49,65,70,74 Pooled estimates showed mortality to be twice as high among HIV+ than among HIV people who inject drugs (CMR ratio: 1.99) (Fig. 11). Further analyses across 13 studies conducted on HIV+ people who inject drugs showed no significant difference in deaths from drug overdose and from AIDS in this group (CMR ratio: 1.35; P = 0.554) (Fig. 12).28,3336,38,39,41,49,65,70,71,74
Only four studies presented data by sex and HIV status.37,47,49,74 They showed no significant difference in CMRs between HIV+ males and HIV+ females who inject drugs (CMR ratio: 1.13; Fig. 13), but HIV males had a pooled CMR 1.81 times greater than that of HIV females who inject drugs (Fig. 14).
Mortality by primary drug injected at baseline
Five studies estimated mortality by primary drug injected (opioids versus stimulants) (Table 2). Pooled estimates of all-cause mortality by primary type of drug injected showed no overall difference across studies (CMR ratio: 1.25; 95% CI: 0.602.61; P = 0.553).36,46,57,70,71 The same was true of studies of mortality resulting from drug overdose (CMR ratio: 1.85; 95% CI: 0.754.56; P = 0.18). In three of the four studies mortality associated with drug overdose was higher among people injecting opioids than among those injecting stimulants.36,46,71 In the fourth study, people who injected primarily stimulants had higher rates of drug overdose; however, the deaths from overdose in this group were later shown to have been caused by opioid use.57
Mortality according to treatment
Six studies provided information on mortality during in-treatment and off-treatment periods at follow-up: the meta-analysis suggested that mortality was 2.52 times higher during off-treatment periods than during in-treatment periods (Fig. 15).22,23,25,26,35,37
Heterogeneity in mortality
We performed univariate analyses to determine if the heterogeneity in overall CMRs and SMRs could be explained by participant characteristics and methodological variables. The results showed that high-income countries had lower CMRs than low- and middle-income countries (Fig. 16). Cohorts with greater proportions of males and HIV+ participants at baseline also had higher CMRs. Cohorts whose follow-up periods ended in more recent years had lower SMRs (Table 3). Study data were not sufficient to allow for multivariate analyses.
Although previous reviews have examined mortality among people who inject drugs, to our knowledge this is the most comprehensive systematic review of the topic and the first to employ novel approaches to search for the available evidence. These approaches ranged from standard searches of the peer-reviewed literature to comprehensive searches of the non-peer reviewed literature and multiple expert consultations, as well as examination of both participant- and study-level factors potentially associated with the risk of death.
The pooled CMR of 2.35 deaths per 100 PY provides evidence of the high mortality associated with injecting drug use. The pooled SMR of 14.68 also shows that mortality is much higher in those who inject drugs than in the general population. Differences by sex were evident: across all studies that reported mortality by sex, males had higher CMRs, yet females who inject drugs had a much higher elevation in mortality relative to their age-matched peers in the general population than did males who inject drugs.
Most of the cohorts identified were from 14 high-income countries; together these 14 counties represent 78% of the total estimated population of people who inject drugs in such countries.76 Studies from only 11 low or middle income countries were identified; these countries account for only 40% of the estimated number of people injecting drugs in low- or middle-income countries.76
Although pooled CMRs were higher among people injecting drugs in low- and middle-income countries rather than high-income countries, we observed no significant difference in pooled SMRs. This suggests that the higher CMRs may reflect higher overall mortality in the general population in low- and middle-income countries than in high-income countries. The lowest and highest mortality rates were documented in cohorts in Australasia and Asia, respectively. Differences across high-income countries probably reflect differences in HIV infection prevalence, coverage of HIV prevention and coverage of opioid agonist maintenance treatment.76,77
Drug overdose and AIDS-related mortality were by far the most common causes of death. The pooled CMR for death from drug overdose was 0.62 per 100 PY, higher among males than females who inject drugs, and higher among HIV+ people who inject drugs than among those who were HIV. In three of the four studies comparing drug overdose among people injecting opioids compared to those injecting stimulants, CMRs were higher among the former group, as expected.36,46,71 In a fourth study, however, drug overdose was higher among people who injected stimulants,57 although further investigation revealed that the deaths from overdose in this group were more often linked to the injection of opioids than to the injection of stimulants. This finding highlights the fact that people who inject drugs often use more than one drug type, even if they have a particular drug of choice.
The prevalence of HIV infection varied widely. As expected, overall mortality was much higher among HIV+ than among HIV people who inject drugs (pooled CMR ratio: 3.15), but mortality from causes other than AIDS was also higher among those who were HIV+. Overdose-related mortality was also higher among HIV+ people who inject drugs in many cohorts. These differences in mortality may reflect differences in risky behaviour, physical health and social disadvantage.
The observational evidence examined in this review is consistent with the evidence from randomized controlled trials that opioid agonist maintenance treatment is associated with a reduced risk of death.78 Among cohorts for which in-treatment and off-treatment periods were carefully tracked, mortality rates were around 2.5 times higher in off-treatment periods than in in-treatment periods. Variation in exposure to treatment could also explain differences between cohorts in mortality from drug overdose, although this variation was not explicitly measured across cohorts.
The prevention of HIV transmission among people who inject drugs is clearly a public health priority.79,80 There is growing evidence that opioid agonist maintenance treatment, antiretroviral treatment and needle and syringe programmes reduce HIV transmission.8183 These interventions have been implemented in many countries, but often on a limited scale only.77 Clearly, however, AIDS is only one of several common causes of death in this group: a comprehensive approach to improving health outcomes among people who inject drugs must also include efforts to reduce other causes of death frequently found among them, particularly drug overdose.84
Limitations of the evidence
Evidence on mortality rates among users of injecting drugs is still predominantly from high-income countries, particularly in western Europe. Interestingly, however, this review has shown that despite marked differences in CMRs across countries, the extent to which this mortality exceeds that of the general population may show less pronounced differences. It would be inappropriate to assume that mortality is equally high among all people who inject drugs. New research in this area is needed, especially in countries where drug injecting is taking place but little research has been conducted about it.
In this review we found no significant differences in the risk of death by type of primary drug injected. This contrasts with the findings of other reviews of people dependent on different drug types, which, despite their own limitations, have suggested differences in mortality among opioid-, amphetamine- and cocaine-dependent persons.35 An explanation for this discrepancy might lie in the extent of drug injection among the groups examined, whether people used multiple drugs (polydrug use being the norm), or the possibility, seldom examined, that some people in the cohorts switched from one primary drug to another during the follow-up period. All of these factors would have reduced our capacity to detect any differences in mortality among people injecting different types of drugs.
The ability to detect differences in mortality in cohort studies according to HIV status is subject to limitations. HIV status was typically measured at baseline only, and some subjects who contracted HIV infection during follow-up would remain assigned to the HIV group for the entire follow-up period. Nonetheless, this would only serve to underestimate the relative differences in mortality between HIV+ and HIV people who inject drugs. The markedly higher all-cause mortality that we observed among HIV+ people who inject drugs is therefore probably a conservative estimate of the elevation in mortality in that group. Misattribution of cause of death as either AIDS- or non-AIDS-related could have occurred as well.
Treatment for HIV infection has improved greatly and has become more widely available. In some cohorts, mortality was examined for the periods before and after highly active antiretroviral therapy (HAART) was introduced. The findings suggest that mortality among HIV+ people who inject drugs decreased after the widespread introduction of HAART.55 Unfortunately, we were unable to examine the impact of treatment for HIV infection across studies because mortality was rarely reported separately for the periods before and after the introduction of HAART.77 However, the observed association between cohorts with more recent follow-up periods and lower SMRs might have to do with the greater availability in recent years of effective interventions for the prevention and treatment of HIV infection.
Reporting quality was poor. Few studies met criteria in consensus statements for the reporting of observational studies.7 Mortality estimates were reported in various forms, including odds ratios, relative risks, hazard ratios and CMRs. Most studies did not report SMRs and many failed to report standard parameters such as PY, or were seldom easy to calculate, particularly for disaggregated mortality estimates. As a result, only a subset of studies could be included in many of the analyses.
Causes of death were not uniformly or consistently coded. Deaths from drug overdose might have been missed in countries with limited capacity to conduct toxicological tests or where recording a death as being from a drug overdose is surrounded by stigma. As a result, we may have underestimated CMRs and SMRs for death from drug overdose. Misattribution of deaths by HIV status may have occurred, since most cohorts were assessed for HIV status at the beginning of the study only and people infected during follow-up could have been missed. Again, this may have resulted in conservative estimates of mortality among HIV+ people who inject drugs and in lower effect sizes. In future research, assessing individuals' HIV status at several time points during the follow-up period would allow a more accurate measurement of mortality in relation to HIV status.
Limitations of the review and meta-analysis
Our review has limitations. The lag time between the date when the studies were conducted and when they were published in peer-reviewed journals was generally long. In light of this we used several methods to search for published and unpublished studies. We reviewed primarily English-language papers, although we also reviewed the abstracts of non-English-language peer-reviewed articles when they were available in English. When studies seemed relevant, we had them translated; we engaged experts from a range of different countries and language groups to review these reference lists. Meta-analytical methods were originally developed to aggregate the findings of randomized controlled trials,85 which have the advantage of allowing for control or adjustment of pre-conditions and sample-related factors that could influence the outcomes of interest. Controlling for such factors is not possible in observational studies, like the ones included in our review.
People who inject drugs have a much higher risk of death than those who do not. Major causes of death in this group are often poorly specified, but death from drug overdose is common, as is AIDS-related mortality in settings with a high prevalence of HIV infection. HIV+ people who inject drugs have higher mortality not just from HIV-related causes but also from drug overdose. Mortality varies by participant- and study-level characteristics, which suggests that multiple factors contribute to the higher risk of death observed in people who inject drugs. Many of these factors are probably modifiable, since certain predominant causes of death account for most of the mortality observed in this group.
Competing interests: None declared.
1. Darke S, Degenhardt L, Mattick RP, editors. Mortality amongst illicit drug users. Cambridge: Cambridge University Press; 2006.
2. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006;82:iii5663. doi:10.1136/sti.2005.019273 PMID:16735295
3. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2011;113:8895. doi:10.1016/j.drugalcdep.2010.07.026 PMID:20828942
4. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend 2009;105:18. doi:10.1016/j.drugalcdep.2009.05.028 PMID:19631479
5. Degenhardt L, McLaren J, Ali H, Briegleb C; Global Burden of Disease Mental Disorders and Illicit Drug Use Expert Group. Methods used in a systematic review of mortality among dependent users of heroin and other opioids. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2008 (Illicit drugs discussion paper No. 9).
6. Calabria B, Phillips B, Singleton J, Mathers BM, Congreve E, Degenhardt L, et al. Searching the grey literature to access information on drug and alcohol research: A resource to identify drug related databases and websites. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2008.
7. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:80535. doi:10.1097/EDE.0b013e3181577511 PMID:18049195
8. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend 2004;76(Suppl):S119. doi:10.1016/j.drugalcdep.2004.08.003 PMID:15555812
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:17788. doi:10.1016/0197-2456(86)90046-2 PMID:3802833
10. Sharp S, Sterne J. Meta-analysis. Stata Tech Bull 1997;38:914.
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:55760. doi:10.1136/bmj.327.7414.557 PMID:12958120
12. Sharp S, Sterne J. Meta-analysis regression. Stata Tech Bull 1998;42:1624.
13. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693708. doi:10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V PMID:10521860
14. Antolini G, Pirani M, Morandi G, Sorio C. Differenze di genere e mortalità in una coorte di eroinomani nelle province emiliane di Modena e Ferrara [Gender difference and mortality in a cohort of heroin users in the Provinces of Modena and Ferrara, 19751999]. Epidemiol Prev 2006;30:919. PMID:16909957
15. Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R et al. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008;43:212444. doi:10.1080/10826080802344583 PMID:19085439
16. Azim T, Khan SI, Nahar Q, Reza M, Alam N, Saifi R, et al. 20 years of HIV in Bangladesh: experiences and way forward. Washington: World Bank; 2009.
17. Bargagli AM, Sperati A, Davoli M, Forastiere F, Perucci CA. Mortality among problem drug users in Rome: an 18-year follow-up study, 198097. Addiction 2001;96:145563. doi:10.1046/j.1360-0443.2001.961014559.x PMID:11571064
18. Bauer SM, Loipl R, Jagsch R, Gruber D, Risser D, Thau K et al. Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 2008;14:8291. doi:10.1159/000113722 PMID:18334818
19. Brancato V, Delvecchio G, Simone P. Sopravvivenza e mortalità in una coorte di tossicodipendenti da eroina nel periodo 19851994 [Survival and mortality in a cohort of heroin addicts in 19851994]. Minerva Med 1995;86:979. PMID:7603612
20. Cardoso MN, Caiaffa WT, Mingoti SA. Projeto AjUDE-Brasil II. AIDS incidence and mortality in injecting drug users: the AjUDE-Brasil II Project. Cad Saude Publica 2006;22:82737. doi:10.1590/S0102-311X2006000400021 PMID:16612436
21. Ciccolallo L, Morandi G, Pavarin R, Sorio C, Buiatti E. La mortalità dei tossicodipendenti nella Regione Emilia Romagna e i suoi determinanti. Risultati di uno studio longitudinale [Mortality risk in intravenous drug users in Emilia Romagna region and its socio-demographic determinants. Results of a longitudinal study]. Epidemiol Prev 2000;24:7580. PMID:10863848
22. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008;94:1517. doi:10.1016/j.drugalcdep.2007.11.003 PMID:18155364
23. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475. doi:10.1136/bmj.c5475 PMID:20978062
24. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 19802001. Arch Intern Med 2004;164:121420. doi:10.1001/archinte.164.11.1214 PMID:15197047
25. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M et al. VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102:19549. doi:10.1111/j.1360-0443.2007.02025.x PMID:18031430
26. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:915. doi:10.1016/j.drugalcdep.2009.05.021 PMID:19608355
27. DiGiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004;99:45060. doi:10.1111/j.1360-0443.2004.00654.x PMID:15049745
28. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993;22:31520. doi:10.1093/ije/22.2.315 PMID:8505190
29. Esteban J, Gimeno C, Barril J, Aragonés A, Climent JM, de la Cruz Pellín M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend 2003;70:193200. doi:10.1016/S0376-8716(03)00002-4 PMID:12732413
30. European Monitoring Centre on Drugs and Drug Addiction. Mortality related to drug use in Europe: public health implications. Lisbon: EMCDDA; 2011.
31. Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol 2012;175:3028. doi:10.1093/aje/kwr318 PMID:22227793
32. Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F et al. Gruppo di studio VEdeTTE. Mortalità in una coorte di tossicodipendenti da eroina arruolati presso i Ser.T in Italia, 19982001 [Mortality of drug users attending public treatment centers in Italy 19982001: a cohort study]. Epidemiol Prev 2007;31:27682. PMID:18274231
33. Fingerhood M, Rastegar DA, Jasinski D. Five year outcomes of a cohort of HIV-infected injection drug users in a primary care practice. J Addict Dis 2006;25:338. doi:10.1300/J069v25n02_05 PMID:16785217
34. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 19821994. Addiction 1997;92:41927. doi:10.1111/j.1360-0443.1997.tb03373.x PMID:9177063
35. Fugelstad A, Rajs J, Böttiger M, Gerhardsson de Verdier M. Mortality among HIV-infected intravenous drug addicts in Stockholm in relation to methadone treatment. Addiction 1995;90:7116. doi:10.1111/j.1360-0443.1995.tb02209.x PMID:7795507
36. Fugelstad A, Annell A, Rajs J, Agren G. Mortality and causes and manner of death among drug addicts in Stockholm during the period 19811992. Acta Psychiatr Scand 1997;96:16975. doi:10.1111/j.1600-0447.1997.tb10147.x PMID:9296546
37. Fugelstad A, Agren G, Romelsjö A. Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment. Subst Use Misuse 1998;33:280317. doi:10.3109/10826089809059352 PMID:9869445
38. Galli M, Musicco M; COMCAT Study Group. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. AIDS 1994;8:145763. doi:10.1097/00002030-199410000-00013 PMID:7818817
39. Goedert JJ, Pizza G, Gritti FM, Costigliola P, Boschini A, Bini A et al. Mortality among drug users in the AIDS era. Int J Epidemiol 1995;24:120410. doi:10.1093/ije/24.6.1204 PMID:8824864
40. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001;15:1295302. doi:10.1097/00002030-200107060-00012 PMID:11426075
41. Golz J, Moll A, Nzimegne S, Klausen G, Schleehauf D. Comparison of antiretroviral therapy in IVDU and MSM a retrospective study 1996-2000. Suchtmedizin in Forschung und Praxis. 2001;3:2533.
42. Haarr D, Nessa J. Opioidbehandling av rusmiddelavhengige i en allmennpraksis [Treatment of opiate-dependent patients in a general practice]. Tidsskr Nor Laegeforen 2007;127:17702. PMID:17599124
43. Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R et al. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health 2003;80:27487. doi:10.1093/jurban/jtg030 PMID:12791803
44. Jafari S, Rahimi-Movahgar A, Craib K, Baharlou S, Mathias R. A follow-up study of drug users in Southern Iran. Addict Res Theory 2010;18:5970. doi:10.3109/16066350902825930
45. Jarrin I, Lumbreras B, Ferreros I, Pérez-Hoyos S, Hurtado I, Hernández-Aguado I. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART. Int J Epidemiol 2007;36:18794. doi:10.1093/ije/dyl231 PMID:17085455
46. Lejckova P, Mravcik V. Mortality of hospitalized drug users in the Czech Republic. J Drug Issues 2007;37:10318. doi:10.1177/002204260703700105
47. Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY et al. Mortality of HIV infected clients treated with methadone maintenance treatment in Yili Kazakh autonomous prefecture. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45:97984. InChinese PMID:22336271
48. Lumbreras B, Jarrín I, del Amo J, Pérez-Hoyos S, Muga R, García-de la Hera M et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006;20:1116. doi:10.1097/01.aids.0000196164.71388.3b PMID:16327326
49. Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. Coll Antropol 2006;30:47988. PMID:17058511
50. McAnulty JM, Tesselaar H, Fleming DW. Mortality among injection drug users identified as "out of treatment". Am J Public Health 1995;85:11920. doi:10.2105/AJPH.85.1.119 PMID:7832249
51. Mezzelani P, Quaglio GL, Venturini L, Lugoboni F, Friedman SR, Des Jarlais DC. A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death. AIDS Care 1998;10:617. doi:10.1080/713612356 PMID:9536202
52. Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007;4:1. doi:10.1186/1477-7517-4-1 PMID:17201933
53. Moroni M, Galli M. Causes of death in a cohort of intravenous-drug-users (IVDUs) recruited in Milan. AIDS Res Hum Retroviruses 1991;7:2412.
54. Moskalewicz J, Sierosławski J. Umieralność osób uzaleznionych od narkotyków przyjmowanych w iniekcjach [Mortality of narcotic addicts using injections]. Przegl Epidemiol 1996;50:32332. InPolish PMID:8927745
55. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007;45:3706. doi:10.1086/519385 PMID:17599317
56. Nyhlén A, Fridell M, Bäckström M, Hesse M, Krantz P. Substance abuse and psychiatric co-morbidity as predictors of premature mortality in Swedish drug abusers: a prospective longitudinal study 19702006. BMC Psychiatry 2011;11:12231. doi:10.1186/1471-244X-11-122 PMID:21801441
57. O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health 2001;91:9847. doi:10.2105/AJPH.91.6.984 PMID:11392946
58. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994;89:1299308. doi:10.1111/j.1360-0443.1994.tb03309.x PMID:7804091
59. Quan VM, Vongchak T, Jittiwutikarn J, Kawichai S, Srirak N, Wiboonnatakul K et al. Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand. Addiction 2007;102:4416. doi:10.1111/j.1360-0443.2006.01709.x PMID:17298652
60. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, Celentano DD et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction 2011;106:5839. doi:10.1111/j.1360-0443.2010.03175.x PMID:21054619
61. Rahimi-Movahgar A, Khastoo G, Razzaghi EM, Saberi-Zafarghandi MB, Noroozi AR, Jar-Siah R. Compulsory methadone maintenance treatment of severe cases of drug addiction in a residential setting in Tehran, Iran: outcome evaluation in two and six-month follow-up. Payesh 2011;10:50312.
62. Reece AS. Favorable mortality profile of naltrexone implants for opiate addiction. J Addict Dis 2010;29:3050. doi:10.1080/10550880903435988 PMID:20390697
63. Sánchez-Carbonell X, Seus L. Ten-year survival analysis of a cohort of heroin addicts in Catalonia: the EMETYST project. Addiction 2000;95:9418. doi:10.1046/j.1360-0443.2000.95694110.x PMID:10946442
64. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998;316:4268. doi:10.1136/bmj.316.7129.426 PMID:9492665
65. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS et al. Mortality among injection drug users in Chennai, India (20052008). AIDS 2009;23:9971004. doi:10.1097/QAD.0b013e32832a594e PMID:19367155
66. Sørensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005;111:2449. doi:10.1111/j.1600-0447.2004.00445.x PMID:15701109
67. Stenbacka M, Leifman A, Romelsjo A. Mortality among opiate abusers in Stockholm: a longitudinal study. Heroin Addict Rel Clin Prob 2007;9:419.
68. Stoové MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008;96:2815. doi:10.1016/j.drugalcdep.2008.03.006 PMID:18434044
69. Tait RJN, Ngo HTT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008;35:11624. doi:10.1016/j.jsat.2007.08.014 PMID:17931824
70. van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996;143:38091. doi:10.1093/oxfordjournals.aje.a008752 PMID:8633622
71. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005;161:9991012. doi:10.1093/aje/kwi133 PMID:15901620
72. Vlahov D, Wang C, Ompad D, Fuller CM, Caceres W, Ouellet L et al.; Collaborative Injection Drug User Study. Mortality risk among recent-onset injection drug users in five US cities. Subst Use Misuse 2008;43:41328. doi:10.1080/10826080701203013 PMID:18365941
73. Zábranský T, Csémy L, Grohmannová K, Janíková B, Brenza J. Mortality of cohort of very young injecting drug users in Prague, 19962010. Cent Eur J Public Health 2011;19:1527. PMID:22026292
74. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994;8:34550. doi:10.1097/00002030-199403000-00008 PMID:8031512
75. Zhang L, Ruan YH, Jiang ZQ, Yang ZN, Liu SZ, Zhou F et al. [A 1-year prospective cohort study on mortality of injecting drug users]. Zhonghua Liu Xing Bing Xue Za Zhi 2005;26:1903. PMID:15941506
76. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA. Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:173345. doi:10.1016/S0140-6736(08)61311-2 PMID:18817968
77. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R et al. Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and country level coverage. Lancet 2010;375:101428. doi:10.1016/S0140-6736(10)60232-2 PMID:20189638
78. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;3:CD002209. PMID:19588333
79. Declaration of Commitment on HIV/AIDS United Nations special session on HIV/AIDS. In: Twenty-sixth special session of the General Assembly of the United Nations. 25-27 June 2001. New York, United States of America; 2001.
80. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al. Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:173345. doi:10.1016/S0140-6736(08)61311-2 PMID:18817968
81. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and HIV transmission among injecting drug users: a review of reviews. Addiction 2010;105:84459. doi:10.1111/j.1360-0443.2009.02888.x PMID:20219055
82. Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington: Institute of Medicine; 2007.
83. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are required. Lancet 2010;376:285301. doi:10.1016/S0140-6736(10)60742-8 PMID:20650522
84. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 2005;100:182331. doi:10.1111/j.1360-0443.2005.01259.x PMID:16367983
85. Kulinskaya E, Morgenthaler S, Staudte R. Meta analysis: a guide to calibrating and combining statistical evidence. Wiley-Interscience; 2008.
(Submitted: 31 May 2012 Revised version received: 26 November 2012 Accepted: 28 November 2012)